双侧乳腺癌 (BC) 的发病率为 1% 至 3%。本研究旨在描述双侧 BC 的临床病理特征和治疗，评估无病生存 (DFS)，并将 DFS 与单侧 BC 进行比较。对双侧浸润性 BC 或单侧浸润性 BC 和对侧导管癌患者进行回顾性分析2008 年至 2022 年在罗切斯特梅奥诊所接受原位导管原位癌 (DCIS) 治疗。使用 4:1 匹配的单侧侵袭性 BC 患者队列进行比较。使用 Wilcoxon 秩和或卡方检验对各组进行比较。采用Kaplan-Meier法和对数秩检验对无病生存率进行分析，并采用Cox比例风险回归进行多变量分析。该研究共确定了278例双侧乳腺癌（其中双侧浸润癌177例，单侧浸润癌101例）。具有对侧 DCIS 的癌症），占侵袭性 BC 的 4.1%。 79.8% 的患者两侧生物亚型一致。 76.6% 的患者初次手术为双侧乳房切除术，20.5% 的患者进行双侧乳房肿瘤切除术，2.9% 的患者进行单侧乳房切除术加单侧乳房肿瘤切除术。 21.7% 的测试者中存在乳腺癌易感基因的致病变异。双侧 BC 患者的 cT 类别高于单侧 BC 患者 (p = 0.02)，并且 ILC 患者比例较高（17.3 % vs 10.9 %；p = 0.004）、雌激素受体阳性 (ER) ）疾病（89.2 % vs 84.2 %；p = 0.04）、多中心/多灶性疾病（37.1 % vs 24.3 %；p < 0.001）、乳腺癌致病变异（21.7 % vs 12.4 %；p = 0.02）和可触及的表现（ 48.2% 与 40.8%；p = 0.03）。双侧 BC 患者的 DFS 与单侧 BC 队列相似 (p = 0.71)。双侧 BC 最常见的是两侧之间的生物学一致性。双侧 BC 更常见于较大的肿瘤、小叶组织学、ER 状态、多中心或多灶性、致病变异和可触及的疾病。双侧 BC 与单侧 BC 相比，DFS 并不差。© 2023。外科肿瘤学会。

Bilateral breast cancer (BC) has an incidence of 1 to 3 %. This study aimed to describe the clinicopathologic characteristics and management of bilateral BC, estimate disease-free survival (DFS), and compare DFS with unilateral BC.A retrospective analysis was performed for patients who had bilateral invasive BC or unilateral invasive BC and contralateral ductal carcinoma in situ (DCIS) treated at Mayo Clinic Rochester from 2008 to 2022. A 4:1 matched cohort of patients with unilateral invasive BC was used for comparison. The groups were compared using Wilcoxon rank-sum or chi-square tests. Disease-free survival was analyzed using the Kaplan-Meier method and log-rank test, with Cox proportional hazards regression used for multivariable analysis.The study identified 278 cases of bilateral breast cancer (177 cases of bilateral invasive cancer and 101 cases of unilateral invasive cancer with contralateral DCIS), representing 4.1 % of invasive BCs. Biologic subtype was concordant between sides in 79.8 % of the patients. Initial surgery was bilateral mastectomy for 76.6 %, bilateral lumpectomy for 20.5 %, and unilateral mastectomy with unilateral lumpectomy for 2.9 % of the patients. Pathogenic variants in breast cancer predisposition genes were present in 21.7 % of those tested. The patients who had bilateral BC presented with a higher cT category than the patients who had unilateral BC (p = 0.02), and a higher proportion presented with ILC (17.3 % vs 10.9 %; p = 0.004), estrogen receptor-positive (ER+) disease (89.2 % vs 84.2 %; p = 0.04), multicentric/multifocal disease (37.1 % vs 24.3 %; p < 0.001), breast cancer pathogenic variant (21.7 % vs 12.4 %; p = 0.02), and palpable presentation (48.2 % vs 40.8 %; p = 0.03). The patients with bilateral BC showed DFS similar to that for the unilateral BC cohort (p = 0.71).Bilateral BCs most commonly are biologically concordant between sides. Bilateral BC presented more commonly with larger tumors, lobular histology, ER+ status, multicentricity or multifocality, pathogenic variant, and palpable disease. Bilateral BC is not associated with worse DFS than unilateral BC.© 2023. Society of Surgical Oncology.